VolitionRX Q4 Earnings Call Highlights

VolitionRX (NYSEAMERICAN:VNRX) outlined what management described as a "transformational" period during its full fiscal year 2025 earnings call, highlighting early steps toward routine clinical use of its Nu.Q platform in both sepsis detection and lung cancer management, alongside continued progress in licensing discussions and cost reductions. Clinical and commercial highlights: sepsis and lung cancer Group